Blanket Purchase Agreement V797D40284-VA797P15A0008

This Blanket Purchase Agreement was awarded by the Department of the Army Medical Command to Nephron Sterile Compounding Center LLC on March 1, 2020, with a potential value of $2.5 million. The BPA is for specialized compounded intravenous solutions with no set-aside used. The period of performance extends through the last date to order of September 30, 2023. The BPA facilitates recurring orders for specific pharmaceutical products and supplies, including Phenylephrine HCI Injection,...

The provided information describes a Blanket Purchase Agreement (BPA) contract vehicle awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Amylyx Pharmaceuticals Inc., a self-certified small disadvantaged business. The single-award BPA, valued at $50,000, enables VA facilities nationwide to order the pharmaceutical product RELYVRIO through June 2024. RELYVRIO, containing the active ingredients sodium phenylbutyrate and taurursodiol, is indicated for the...

The government has awarded a Blanket Purchase Agreement (BPA) to Nephron Sterile Compounding Center LLC, a woman-owned limited liability company, to provide pharmaceutical products and supplies to the Defense Health Agency (DHA). The BPA has a ceiling value of $4,000,000 and a period of performance through March 31, 2025. Under this BPA, Nephron has received two specific task orders to date. The first is a $20,625 firm fixed price award for various injectable pharmaceutical products including...

The U.S. Department of Veterans Affairs National Acquisition Center has awarded a single-award Blanket Purchase Agreement (BPA) to Kyowa Kirin, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the procurement of Nourianz, an FDA-approved adjunctive treatment for Parkinson's disease "off" episodes. This BPA has a ceiling value of $687,460 and a period of performance through October 5, 2025. In addition to the BPA, Kyowa Kirin, Inc. holds a multiple-award Federal Supply...

The Department of Veterans Affairs National Acquisition Center awarded a single-award Blanket Purchase Agreement to Urogen Pharma Inc. The BPA has a potential value of $1.5 million and expires on February 3, 2021. It was established on October 2, 2020 to procure Jelmyto, a treatment for low-grade upper tract urothelial cancer. As the sole awardee, Urogen Pharma will provide its product Jelmyto to the VA National Acquisition Center through this BPA. Jelmyto is an FDA-approved medication for the...

This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian agency, to Otsuka America Pharmaceutical Inc., a large pharmaceutical manufacturer. The $83,342,090.00 BPA is for the supply of the drug Jynarque (tolvaptan) to the Department of Veterans Affairs (VA) healthcare system. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs, to Astellas Pharma US, Inc., a foreign-owned for-profit pharmaceutical manufacturer. The BPA has a ceiling value of $296,500.00 and a period of performance through October 6, 2025. The purpose of this BPA is to facilitate the procurement of the oncology drugs XTANDI and XOSPATA by the VA and potentially other federal agencies. This BPA was established...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center of the U.S. Department of Veterans Affairs (VA) to Urogen Pharma Inc., a pharmaceutical company specializing in the drug JELMYTO. The single-award BPA, valued at up to $2.5 million, was made under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is valid through February 2026. The purpose of this BPA is to provide the VA with a streamlined procurement vehicle to order JELMYTO, a drug used to...

The subject federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a division of the U.S. Department of Veterans Affairs (VA), to Amylyx Pharmaceuticals Inc. (Amylyx). The BPA, valued at $50,000, is for the procurement of RELYVRIO, an FDA-approved treatment for amyotrophic lateral sclerosis (ALS) developed by Amylyx. As a self-certified small disadvantaged business, Amylyx has established several contract vehicles with the VA to facilitate the...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Civica Inc., a non-profit organization and manufacturer of goods. The BPA has a ceiling value of $625,000.00 and a period of performance ending on April 3, 2026. The BPA is for the procurement of the pharmaceutical products daptomycin, lorazepam, phenylephrine, and anectine. As a BPA, this contract vehicle allows the agency to place individual task orders for these products as needed...